CSLs subsidiary Seqirus opened a stateoftheart $1 billion cellbased influenza vaccine and antivenom manufacturing facility in Melbourne at the end of 2025, the only one of its kind in the Southern Hemisphere and one of just three worldwide, significantly boosting Australias sovereign production of seasonal and pandemic flu vaccines, antivenoms and Q fever vaccines
They also have a number of emergent uses and a range of side effects
In the MASLD (metabolic dysfunction-associated steatotic liver disease) substudy, participants on the 12 mg dose achieved greater than 85% liver fat normalization
These models offer a data-driven basis for evaluating genetic and regulatory elements vulnerable to heat stress in the context of changing environmental conditions
Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes
Greater receptor binding: Semaglutide binds more effectively to GLP-1 receptors, producing stronger signaling